KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Royalty Pharma (RPRX) EPS (Basic) (2020 - 2025)

Royalty Pharma (RPRX) has disclosed EPS (Basic) for 6 consecutive years, with $0.5 as the latest value for Q4 2025.

  • Quarterly EPS (Basic) rose 6.38% to $0.5 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.79 through Dec 2025, down 7.25% year-over-year, with the annual reading at $1.79 for FY2025, 6.77% down from the prior year.
  • EPS (Basic) hit $0.5 in Q4 2025 for Royalty Pharma, down from $0.67 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of $1.22 in Q3 2024 to a low of -$1.04 in Q4 2022.
  • Historically, EPS (Basic) has averaged $0.4 across 5 years, with a median of $0.4 in 2024.
  • Biggest five-year swings in EPS (Basic): crashed 903.76% in 2022 and later skyrocketed 5400.0% in 2025.
  • Year by year, EPS (Basic) stood at $0.13 in 2021, then tumbled by 903.76% to -$1.04 in 2022, then skyrocketed by 206.73% to $1.11 in 2023, then crashed by 57.66% to $0.47 in 2024, then rose by 6.38% to $0.5 in 2025.
  • Business Quant data shows EPS (Basic) for RPRX at $0.5 in Q4 2025, $0.67 in Q3 2025, and $0.07 in Q2 2025.